The Role of Fas/Fas Ligand System in the Pathogenesis of Liver Cirrhosis and Hepatocellular Carcinoma

Hepatitis Monthly

Volumn 12, Issue 11, 2012, Pages

  Hammam, Olfat ^a   Mahmoud, Ola ^a   Zahran, Manal ^a   Aly, Sohair ^b   Hosny, Karim ^c   Helmy, Amira ^a   Anas, Amgad ^a  

^a THEODOR BILHARZ RESEARCH INSTITUTE   (Egypt)

^b NRC   (Egypt)

^c Cairo University   (Egypt)

Author keywords

Carcinoma, Hepatocellular; Liver Cirrhosis; SfaS Protein

Indexed keywords

EID: 84982857288     PISSN: 1735143X     EISSN: 17353408     Source Type: Journal    
DOI: 10.5812/hepatmon.6132     Document Type: Article

References (40)

1. Coulon S, Heindryckx F, Geerts A, Van Steenkiste C, Colle I, Van Vlierberghe H. Angiogenesis in chronic liver disease and its com-plications. Liver Int. 2011;31(2):146-62.
2. Onji M, Kikuchi T, Kumon I, Masumoto T, Nadano S, Kajino K, et al. Intrahepatic lymphocyte subpopulations and HLA class I antigen expression by hepatocytes in chronic hepatitis C. Hepatogas-troenterol. 1992;39(4):340-3.
3. Ahn J, Chung KS, Kim DU, Won M, Kim L, Kim KS, et al. Systematic identification of hepatocellular proteins interacting with NS5A of the hepatitis C virus. J Biochem Mol Biol. 2004;37(6):741-8.
4. Patel T. Immune escape in hepatocellular cancer: is a good of-fense the best defense? Hepatology. 1999;30(2):576-8.
5. Nagata S. Apoptosis by death factor. Cell. 1997;88(3):355-65.
6. Nagata S, Golstein P. The Fas death factor. Science. 1995;267(5203):1449-56.
7. Bebenek M, Dus D, Kozlak J. Fas expression in primary breast cancer is related to neoplastic infiltration of perilymphatic fat. Adv Med Sci. 2008;53(1):49-53.
8. Viard-Leveugle I, Veyrenc S, French LE, Brambilla C, Brambilla E. Frequent loss of Fas expression and function in human lung tu-mours with overexpression of FasL in small cell lung carcinoma. J Pathol. 2003;201(2):268-77.
9. Suda T, Takahashi T, Golstein P, Nagata S. Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family. Cell. 1993;75(6):1169-78.
10. Griffith TS, Brunner T, Fletcher SM, Green DR, Ferguson TA. Fas ligand-induced apoptosis as a mechanism of immune privilege. Science. 1995;270(5239):1189-92.
11. Lee SH, Kim SY, Lee JY, Shin MS, Dong SM, Na EY, et al. Detection of soluble Fas mRNA using in situ reverse transcription-poly-merase chain reaction. Lab Invest. 1998;78(4):453-9.
12. Pryczynicz A, Guzinska-Ustymowicz K, Kemona A. Fas/FasL expression in colorectal cancer. An immunohistochemical study. Folia Histochem Cytobiol. 2010;48(3):425-9.
13. Nagao M, Nakajima Y, Hisanaga M, Kayagaki N, Kanehiro H, Aomatsu Y, et al. The alteration of Fas receptor and ligand system in hepatocellular carcinomas: how do hepatoma cells escape from the host immune surveillance in vivo? Hepatology. 1999;30(2):413-21.
14. Helmy A, Hammam OA, El Lithy TR, El Deen Wishahi MM. The role of TGF-beta-1 protein and TGF-beta-R-1 receptor in immune escape mechanism in bladder cancer. MedGenMed. 2007;9(4):34.
15. Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology. 1996;24(2):289-93.
16. Hsu SM, Raine L. Protein A, avidin, and biotin in immunohisto-chemistry. J Histochem Cytochem. 1981;29(11):1349-53.
17. Chen N, Bai L, Deng T. Study on pathway of apoptosis in chronic liver disease. Chinese J Infect Dis. 2003;2:016.
18. Itoi T, Yamana K, Bilim V, Takahashi K, Tomita F. Impact of frequent Bcl-2 expression on better prognosis in renal cell carcinoma patients. Br J Cancer. 2004;90(1):200-5.
19. Mansy SS. Agarose cell block: innovated technique for the pro-cessing of urine cytology for electron microscopy examination. Ultrastruct Pathol. 2004;28(1):15-21.
20. Petrie A, Sabin C. Medical Statistics at a Glance. Chichester, West Sussex, UK: John Wiley & Sons; 2009.
21. Bantel H, Schulze-Osthoff K. Apoptosis in hepatitis C virus infec-tion. Cell Death Differ. 2003;10 Suppl 1:S48-58.
22. Fischer R, Baumert T, Blum HE. Hepatitis C virus infection and apoptosis. World J Gastroenterol. 2007;13(36):4865-72.
23. Pelli N, Floreani A, Torre F, Delfino A, Baragiotta A, Contini P, et al. Soluble apoptosis molecules in primary biliary cirrhosis: analysis and commitment of the Fas and tumour necrosis factor-related apoptosis-inducing ligand systems in comparison with chronic hepatitis C. Clin Exp Immunol. 2007;148(1):85-9.
24. Kornmann M, Ishiwata T, Maruyama H, Beger HG, Korc M. Coex-pression of FAS and FAS-ligand in chronic pancreatitis: correla-tion with apoptosis. Pancreas. 2000;20(2):123-8.
25. Leithauser F, Dhein J, Mechtersheimer G, Koretz K, Bruderlein S, Henne C, et al. Constitutive and induced expression of APO-1, a new member of the nerve growth factor/tumor necrosis factor receptor superfamily, in normal and neoplastic cells. Lab Invest. 1993;69(4):415-29.
26. Roskams T, Libbrecht L, Van Damme B, Desmet V. Fas and Fas li-gand: strong co-expression in human hepatocytes surrounding hepatocellular carcinoma; can cancer induce suicide in peritu-moural cells? J Pathol. 2000;191(2):150-3.
27. Mochizuki K, Hayashi N, Hiramatsu N, Katayama K, Kawanishi Y, Kasahara A, et al. Fas antigen expression in liver tissues of patients with chronic hepatitis B. J Hepatol. 1996;24(1):1-7.
28. El Bassiouny AE, El-Bassiouni NE, Nosseir MM, Zoheiry MM, El-Ahwany EG, Salah F, et al. Circulating and hepatic Fas expression in HCV-induced chronic liver disease and hepatocellular carci-noma. Medscape J Med. 2008;10(6):130.
29. Hiramatsu N, Hayashi N, Katayama K, Mochizuki K, Kawanishi Y, Kasahara A, et al. Immunohistochemical detection of Fas antigen in liver tissue of patients with chronic hepatitis C. Hepatol-ogy. 1994;19(6):1354-9.
30. Galle PR, Hofmann WJ, Walczak H, Schaller H, Otto G, Stremmel W, et al. Involvement of the CD95 (APO-1/Fas) receptor and ligand in liver damage. J Exp Med. 1995;182(5):1223-30.
31. Bortolami M, Kotsafti A, Cardin R, Farinati F. Fas / FasL system, IL-1beta expression and apoptosis in chronic HBV and HCV liver disease. J Viral Hepat. 2008;15(7):515-22.
32. Hayashi N, Mita E. Fas system and apoptosis in viral hepatitis. J Gastroenterol Hepatol. 1997;12(9-10):S223-6.
33. El-Bassiouni A, Nosseir M, Zoheiry M, El-Ahwany E, Ghali A, El-Bassiouni N. Immunohistochemical expression of CD95 (Fas), c-myc and epidermal growth factor receptor in hepatitis C virus infection, cirrhotic liver disease and hepatocellular carcinoma. APMIS. 2006;114(6):420-7.
34. Akazawa Y, Gores GJ. Death receptor-mediated liver injury. Semin Liver Dis. 2007;27(4):327-38.
35. Zhang L, Wang X, Zheng W, Shi M. The effects of interleukin-10 on the expression of Fas and FasL in rat hepatic stellate cells. Med Chem. 2006;2(6):611-6.
36. Kawamura T, Azuma M, Kayagaki N, Shimada S, Yagita H, Okumu-ra K. Fas/Fas ligand-mediated apoptosis of murine Langerhans cells. J Dermatol Sci. 2000;22(2):96-101.
37. Hirashima N, Matsumoto Y, Ohono T, Kimura Y, Hasegawa I, Ueda R. Hepatic Fas protein expression might be a predictive factor for hepatocellular carcinoma development in patients with chronic hepatitis C undergoing interferon therapy. J Clin Gastroenterol. 2002;34(3):263-7.
38. Kamegaya Y, Hiasa Y, Zukerberg L, Fowler N, Blackard JT, Lin W, et al. Hepatitis C virus acts as a tumor accelerator by blocking apoptosis in a mouse model of hepatocarcinogenesis. Hepatol-ogy. 2005;41(3):660-7.
39. Peng Z, Tang H, Ling Y, Han G. Apoptosis and Fas system are significantly involved in the process of liver cirrhosis converting into hepatocellular carcinoma. J Tongji Med Univ. 2001;21(2):126-9, 48.
40. Midis GP, Shen Y, Owen-Schaub LB. Elevated soluble Fas (sFas) levels in nonhematopoietic human malignancy. Cancer Res. 1996;56(17):3870-4.